Sarepta Therapeutics (SRPT) Other Working Capital Changes (2013 - 2026)

Sarepta Therapeutics' Other Working Capital Changes history runs 14 years deep, the most recent figure standing at -$274.9 million for Q1 2026.

• On a quarterly basis, Other Working Capital Changes fell 221.93% year-over-year to -$274.9 million in Q1 2026; TTM through Mar 2026 was -$117.5 million, a 74.96% decrease from a year earlier, with the FY2025 full-year figure at $72.1 million, up 324.04% from the prior year.
• Other Working Capital Changes eased to -$274.9 million in Q1 2026 per SRPT's latest filing, from -$28.0 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $122.7 million in Q2 2025 and bottomed at -$274.9 million in Q1 2026.
• The 5-year median for Other Working Capital Changes is -$17.5 million (2022), against an average of -$19.2 million.
• Biggest YoY gain for Other Working Capital Changes was 267.38% in 2024; the steepest drop was 1424.07% in 2024.
• Year by year, Other Working Capital Changes stood at -$22.5 million in 2022, then jumped by 79.13% to -$4.7 million in 2023, then tumbled by 1424.07% to -$71.5 million in 2024, then surged by 60.83% to -$28.0 million in 2025, then sank by 881.18% to -$274.9 million in 2026.
• Per Business Quant, the three latest SRPT Other Working Capital Changes figures stand at -$274.9 million (Q1 2026), -$28.0 million (Q4 2025), and $62.8 million (Q3 2025).